9th Early Detection Research Network (EDRN) Scientific Workshop
September 8-10, 2014
"Biomarkers at a Crossroad in Personalized Cancer Risk Assessment and Detection"
Hyatt Regency Bethesda
Bethesda, Maryland

EDRN Prostate & Urogenital Cancers Collaborative Group Meeting

Tuesday, September 9, 2014
8:00 a.m. – 12:00 p.m.
Baccarat Suite

Chair:
Mark Rubin, M.D., Weill Cornell Medical College

NCI Program Directors:
o   Jacob Kagan, Ph.D., National Cancer Institute
o   Richard Mazurchuk, Ph.D., National Cancer Institute

Agenda

8:00 a.m.– 8:05 a.m.	**Welcome**
	o Mark Rubin, M.D., Weill Cornell Medical College o Jacob Kagan, Ph.D., National Cancer Institute o Richard Mazurchuk, Ph.D., National Cancer Institute
8:05 a.m. – 8:35 a.m.	**Keynote Presentation: Proteomic Signatures for Aggressive Prostate Cancer**
8:05 a.m. – 8:25 a.m.	Ruedi Aebersold, Ph.D., ETH, Institute of Molecular Systems Biology, Zurich, Switzerland
8:25 a.m. – 8:35 a.m.	Discussion
8:35 a.m. – 9:30 a.m.	**Proteomic and Glyco-proteomics Approaches Leading to Prostate Cancer Biomarkers**
8:35 a.m. – 8:50 a.m.	Integrated Analyses of Genome, Proteome and Glycoproteome Reveal Altered Glycosylation in Tumor Subtypes Hui Zhang, Ph.D., John Hopkins University
8:50 a.m. – 9:05 a.m.	Progress on the Ultrasensitive, Multiplexed Quantification of Cancer Biomarkers David Camp, Ph.D., Pacific Northwest National Laboratory
9:05 a.m. – 9:20 a.m.	EDRN Biomarkers Reference Laboratory: Studies of Aggressive Prostate Cancer Biomarkers Daniel Chan, Ph.D., John Hopkins University
9:20 a.m.– 9:30 a.m.	Discussion

9th Early Detection Research Network (EDRN) Scientific Workshop
September 8-10, 2014
"Biomarkers at a Crossroad in Personalized Cancer Risk Assessment and Detection"
Hyatt Regency Bethesda
Bethesda, Maryland

EDRN Prostate & Urogenital Cancers Collaborative Group Meeting

9:30 a.m. – 10:25 a.m.	**Molecular and Biological Approaches Leading to Prostate Cancer Biomarkers**
9:30 a.m. – 9:45 a.m.	Migrating a Multigene Prognostic Profile for Prostate Cancer to FFPE Tissue Dan Mercola, M.D., Ph.D., University of California, Irvine
9:45 a.m.– 10:00 a.m.	Impact of Ethnicity on Prostate Cancer Biomarkers Shiv Srivastava , Ph.D., Center for Prostate Disease Research, Uniform Services University of the Health Sciences
10:00 a.m. – 10:15 a.m.	Multi-marker Urine Analysis for Prostate Cancer o Alvin Liu, Ph.D., University of Washington o Weijun Qian, Ph.D., Pacific Northwest National Laboratory
10:15 a.m. – 10:25 a.m.	Discussion
10:25 a.m. – 11:20 a.m.	**EDRN GU Validation Studies**
10:25 a.m. – 10:40 a.m.	Keeping Prostate Cancer Risk Calculators Current Donna Pauler Ankerst, Ph.D., University of Texas Health Science at San Antonio and Technische Universitaet Muenchen, Germany
10:40 a.m. – 10:55 a.m.	Urinary Markers for Prostate Cancer – What Next? The Interface Between Validation and Clinical Implementation Martin Sanda, M.D., Emory University
10:55 a.m. – 11:10 a.m.	Prognostication in Early Low Risk Prostate Cancer: The Canary - EDRN Collaboration Jim Brooks, M.D., Stanford University
11:10 a.m. – 11:20 a.m.	Discussion
11:20 a.m. – 12:00 p.m.	**CLIA Laboratory Developed Test (LDT)**
11:20 a.m. – 11:35 a.m.	Oncotype DX, Prostate Cancer Assay Steven Shak, M.D., Executive Vice President of Research and Development of Genomic Health Inc.
11:35 a.m. – 11:40 a.m.	Discussion
11:40 a.m. – 11:55 a.m.	The CCP Score: A Novel Genetic Test for Prostate Cancer Prognosis Michael K. Brawer, M.D., Vice President Medical Affairs, Urology, Myriad Genetics Laboratories
11:55 a.m. – 12:00 p.m.	Discussion
12:00 p.m.	**Adjourn**